View the PDF of this article at: https://www.the-jci.org/press/17166.pdf

ACCOMPANYING COMMENTARY:
Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword

CONTACT:
Alberto Pugliese
Diabetes Research Institution, University of Miami, Miami, Florida, USA
Phone : 305-243-5348
Fax : 305-243-4404
E-mail: apuglies@med.miami.edu

View the PDF of this commentary at: https://www.the-jci.org/press/18395.pdf

Activation of the m opioid receptor provides calm for the colon

Excessive inflammation in the intestine is characteristic of inflammatory bowel disease (IBD). Researchers now show that administration beneath the skin of compounds that selectively inhibit the m opioid receptor in the colon are capable of preventing colitis in mice. These results suggest that such compounds may have therapeutic potential in IBD patients.

CONTACT:
Pierre Desreumaux,
Hopital Huriez, Service de Gastro-enterologie, Lille, France.
Phone: 33-3-2044-4714
Fax: 33-3-2044-4713
E-mail: pdesreumaux@chru-lille.fr

View the PDF of this article at: https://www.the-jci.org/press/16750.pdf

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

AUTHOR CONTACT:
Lutz-Henning Block
University of Vienna, Vienna, Austria.
Phone: 43-1-40400-4
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-May-2003